News
-
-
PRESS RELEASE
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a plant-based prescription drug, granted Orphan Drug Designation by FDA & EMA for treating rare pediatric diseases, including short bowel syndrome (SBS) & microvillus inclusion disease (MVID). Study presented at ELITE PED-GI Congress -
-
PRESS RELEASE
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Jaguar Health's crofelemer shows significant results in breast cancer patients for prophylaxis of diarrhea. Late-breaker abstracts on responder analysis and oral mucositis survey results accepted for MASCC's 2025 Annual Meeting -
-
PRESS RELEASE
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Jaguar Health, Inc. (NASDAQ:JAGX) announces Napo Pharmaceuticals' participation in the 50th Oncology Nursing Society Congress to showcase Gelclair® for oral mucositis relief in cancer patients -
-
-
-
PRESS RELEASE
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announces the closing of a private placement, issuing convertible promissory notes and unregistered warrants to selected investors, with gross proceeds of approximately $3.448 million
